A citation-based method for searching scientific literature

Steven H Shen, Karolina Woroniecka, Andrew B Barbour, Peter E Fecci, Luis Sanchez-Perez, John H Sampson. Expert Opin Biol Ther 2020
Times Cited: 13







List of co-cited articles
151 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, Willy Hugo, Alexander H Lee, Tom B Davidson, Anthony C Wang, Benjamin M Ellingson, Julie A Rytlewski, Catherine M Sanders,[...]. Nat Med 2019
395
38

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
38

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
38

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Kurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, Alvaro López-Janeiro, Angelo Porciuncula, Miguel A Idoate, Susana Inogés, Carlos de Andrea, Ascensión López-Diaz de Cerio, Sonia Tejada,[...]. Nat Med 2019
217
30

Virus-Based Immunotherapy of Glioblastoma.
Miika Martikainen, Magnus Essand. Cancers (Basel) 2019
66
30

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
David A Reardon, Alba A Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim Baehring, Manmeet S Ahluwalia, Patrick Roth, Oliver Bähr,[...]. JAMA Oncol 2020
207
30

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim, Charles S Cobbs, Jason A Heth, Michael Salacz, Sarah Taylor, Stacy D D'Andre,[...]. J Transl Med 2018
167
23

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
702
23

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Timothy F Cloughesy, Joseph Landolfi, Michael A Vogelbaum, Derek Ostertag, James B Elder, Stephen Bloomfield, Bob Carter, Clark C Chen, Steven N Kalkanis, Santosh Kesari,[...]. Neuro Oncol 2018
71
23

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives.
Bas Weenink, Pim J French, Peter A E Sillevis Smitt, Reno Debets, Marjolein Geurts. Cancers (Basel) 2020
26
23

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman,[...]. N Engl J Med 2015
23

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
23

Lomustine and Bevacizumab in Progressive Glioblastoma.
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih,[...]. N Engl J Med 2017
316
23

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Hideho Okada, Michael Weller, Raymond Huang, Gaetano Finocchiaro, Mark R Gilbert, Wolfgang Wick, Benjamin M Ellingson, Naoya Hashimoto, Ian F Pollack, Alba A Brandes,[...]. Lancet Oncol 2015
338
23

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto,[...]. Lancet Oncol 2017
419
23

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Hongsheng Miao, Bryan D Choi, Carter M Suryadevara, Luis Sanchez-Perez, Shicheng Yang, Gabriel De Leon, Elias J Sayour, Roger McLendon, James E Herndon, Patrick Healy,[...]. PLoS One 2014
78
23

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
Donald M O'Rourke, MacLean P Nasrallah, Arati Desai, Jan J Melenhorst, Keith Mansfield, Jennifer J D Morrissette, Maria Martinez-Lage, Steven Brem, Eileen Maloney, Angela Shen,[...]. Sci Transl Med 2017
615
23

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
Eric A Reits, James W Hodge, Carla A Herberts, Tom A Groothuis, Mala Chakraborty, Elizabeth K Wansley, Kevin Camphausen, Rosalie M Luiten, Arnold H de Ru, Joost Neijssen,[...]. J Exp Med 2006
974
23

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.
Amit A Lugade, Elizabeth W Sorensen, Scott A Gerber, James P Moran, John G Frelinger, Edith M Lord. J Immunol 2008
287
23

EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
John H Sampson, Bryan D Choi, Luis Sanchez-Perez, Carter M Suryadevara, David J Snyder, Catherine T Flores, Robert J Schmittling, Smita K Nair, Elizabeth A Reap, Pamela K Norberg,[...]. Clin Cancer Res 2014
177
23

Brain immunology and immunotherapy in brain tumours.
John H Sampson, Michael D Gunn, Peter E Fecci, David M Ashley. Nat Rev Cancer 2020
111
23

Chimeric Antigen Receptor Therapy.
Carl H June, Michel Sadelain. N Engl J Med 2018
706
23

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Michael C Burger, Congcong Zhang, Patrick N Harter, Annette Romanski, Florian Strassheimer, Christian Senft, Torsten Tonn, Joachim P Steinbach, Winfried S Wels. Front Immunol 2019
65
23

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
Christine E Brown, Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R Wagner, Araceli Naranjo, Julie R Ostberg, M Suzette Blanchard, Julie Kilpatrick, Jennifer Simpson,[...]. N Engl J Med 2016
710
23

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Andras Heczey, Chrystal U Louis, Barbara Savoldo, Olga Dakhova, April Durett, Bambi Grilley, Hao Liu, Mengfeng F Wu, Zhuyong Mei, Adrian Gee,[...]. Mol Ther 2017
203
23

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Stephanie L Goff, Richard A Morgan, James C Yang, Richard M Sherry, Paul F Robbins, Nicholas P Restifo, Steven A Feldman, Yong-Chen Lu, Lily Lu, Zhili Zheng,[...]. J Immunother 2019
88
23

Current state of immunotherapy for glioblastoma.
Michael Lim, Yuanxuan Xia, Chetan Bettegowda, Michael Weller. Nat Rev Clin Oncol 2018
365
23

Targeting EGFRvIII for glioblastoma multiforme.
Ju Yang, Jing Yan, Baorui Liu. Cancer Lett 2017
25
23

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Michael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, James N Kochenderfer, Sattva S Neelapu, Marcela V Maus, David L Porter, David G Maloney, Stephan A Grupp, Crystal L Mackall,[...]. J Immunother Cancer 2018
90
15


Toxicity and management in CAR T-cell therapy.
Challice L Bonifant, Hollie J Jackson, Renier J Brentjens, Kevin J Curran. Mol Ther Oncolytics 2016
413
15

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies.
Jiali Cheng, Lei Zhao, Yuanyuan Zhang, Yun Qin, Yuqi Guan, Tong Zhang, Chaohong Liu, Jianfeng Zhou. Front Oncol 2019
48
15

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
15

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
15

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
15

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
15

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
Cyril Neftel, Julie Laffy, Mariella G Filbin, Toshiro Hara, Marni E Shore, Gilbert J Rahme, Alyssa R Richman, Dana Silverbush, McKenzie L Shaw, Christine M Hebert,[...]. Cell 2019
399
15

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller, Christopher D Lao,[...]. Lancet Oncol 2015
15

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen, Evanthia Galanis, John Degroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman,[...]. J Clin Oncol 2010
15

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack,[...]. N Engl J Med 2015
15

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf-Dieter Kortmann, Dietmar Krex, Oliver Grauer,[...]. Lancet 2019
153
15

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Patrick Y Wen, Michael Weller, Eudocia Quant Lee, Brian M Alexander, Jill S Barnholtz-Sloan, Floris P Barthel, Tracy T Batchelor, Ranjit S Bindra, Susan M Chang, E Antonio Chiocca,[...]. Neuro Oncol 2020
110
15

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Antonio Omuro, Gordana Vlahovic, Michael Lim, Solmaz Sahebjam, Joachim Baehring, Timothy Cloughesy, Alfredo Voloschin, Shakti H Ramkissoon, Keith L Ligon, Robert Latek,[...]. Neuro Oncol 2018
190
15

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
Andrea Sottoriva, Inmaculada Spiteri, Sara G M Piccirillo, Anestis Touloumis, V Peter Collins, John C Marioni, Christina Curtis, Colin Watts, Simon Tavaré. Proc Natl Acad Sci U S A 2013
969
15

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, Hendrikus J Dubbink, Laurens V Beerepoot, Monique C J Hanse, Jan Buter, Aafke H Honkoop, Dolf Boerman, Filip Y F de Vos,[...]. Lancet Oncol 2014
433
15

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
15

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Catherine Hanna, Kathreena M Kurian, Karin Williams, Colin Watts, Alan Jackson, Ross Carruthers, Karen Strathdee, Garth Cruickshank, Laurence Dunn, Sara Erridge,[...]. Neuro Oncol 2020
20
15

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
15

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
David A Reardon, Annick Desjardins, James J Vredenburgh, Donald M O'Rourke, David D Tran, Karen L Fink, Louis B Nabors, Gordon Li, Daniela A Bota, Rimas V Lukas,[...]. Clin Cancer Res 2020
39
15

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.